Introduction {#Sec1}
============

The impact of cancer on outcome of persons developing coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial \[[@CR1]--[@CR12]\]. Several studies reported an increased risk of death \[[@CR1]--[@CR3], [@CR5]--[@CR9], [@CR13]--[@CR18]\], others not \[[@CR19]--[@CR26]\]. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom also had cancer. We found cancer was an independent risk factor for in-hospital death from COVID-19 in subjects \<65 but not ≥65 years. Subjects with cancer not in complete remission also had an increased risk of death from COVID-19. Risks of death were similar in subjects with solid cancers and those with hematological cancers. These data may help predict outcomes of persons with cancer and COVID-19.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

Between 20 January and 4 April 2020 we studied 1859 consecutive subjects with COVID-19 treated at seven centers of five hospitals of Union Hospital (main part, Union West Hospital and Union Tumor Hospital), Wuhan Central Hospital, General Hospital of Central Theater Command, PLA and Wuhan Jinyintan Hospital. These hospitals were urgently reconstructed by the Chinese government as the designated hospitals and centers for COVID-19 therapy.

Subjects were tested for SARS-CoV-2-infection by qRT-PCR of nasal and pharyngeal swabs and/or blood test for anti-SARS-CoV-2 IgG/IgM antibodies using a colloidal-gold-based 2019-nCoV IgG/IgM Detection Kit (Nanjing Vazyme Medical Technology, Nanjing, China) using criteria of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program of the National Health Commission of China (7th version) \[[@CR27]\] and World Health Organization (WHO) interim guidance \[[@CR28]\]. COVID-19 was diagnosed in neighborhood clinics or Fangcang Hospital before admission to the designated hospitals or in designated hospitals after admission \[[@CR29]\]. Severity of COVID-19 was graded as described \[[@CR2]\]. Subjects were treated as reported \[[@CR30], [@CR31]\] or according to Chinese government guidelines. The study was approved by the Ethics Committees of Union Hospital (2020-0095) and of Wuhan Central Hospital (2020-007). Requirement for informed consent was waived by the Ethics Committees.

Data collection {#Sec4}
---------------

Electronic medical records (EMRs) of subjects including epidemiological, demographic, and laboratory data were reviewed. Outcomes included: (1) death; (2) alive with two successive negative SARS-Cov-2 qRT-PCR tests; (3) interval from symptoms to hospital admission, discharge or death; (4) negative qRT-PCT test; and (5) interval from admission to COVID-19 progression. Data collection forms were reviewed and verified independently by two physicians (WH and JY). A third researcher adjudicated discordances. Data were analyzed as of 24 April 2020.

Definitions {#Sec5}
-----------

Solid cancers and hematological cancers were included. Cancer remission was defined as complete remission for ≥1 year. Exposure history was defined as contact with persons with confirmed SARS-CoV-2 infection or visit to the South China Seafood Wholesale Market. Smoking history was defined as current or former smoker (stopping \>5 years ago) with exposure of ≥20 cigarettes per day for ≥1 year (1 pack year). Fever was defined as temperature ≥37.3 °C. Acute kidney and heart injury and acute respiratory distress syndrome (ARDS) were defined as reported \[[@CR32], [@CR33]\]. Liver injury was defined as ≥1 liver function enzyme activity value ≥2 x upper limit of normal. Invasive and non-invasive mechanical ventilations were defined as mechanical ventilation with or without intubation \[[@CR34], [@CR35]\].

Statistical analysis {#Sec6}
--------------------

Continuous variables with a skewed distribution were described as median (interquartile range, IQR). Categorical variables are presented as number (%). Proportions for categorical variables were compared by *χ*2 test or Fisher exact test. Pearson *χ*2 test was used for contingency data for variables with more than two categories. Mann--Whitney test was used to compare continuous variables. Co-variates associated with risk of in-hospital death from COVID-19 were analyzed in a Cox regression model. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) calculated using the Cox proportional hazard model. Co-variates with *P* \< 0.05 in uni-variable analyses except those with co-linearity were included in multi-variable analyses. Statistical analysis was performed with SPSS 26.0 statistical software (IBM Corporation, New York, United States). A two-sided *P* value \< 0.05 was considered significant.

Results {#Sec7}
=======

Admission demographic and baseline co-variates {#Sec8}
----------------------------------------------

From 20 January to 4 April 2020, 3559 hospitalized persons who died or were discharged with COVID-19 were enrolled, 1859 of whom had quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR)- (*N* = 1790) or IgM/G (*N* = 69)-confirmed SARS-CoV-2-infection were included in the analysis. 1650 survived; 209 died. Age and age distribution, sex, smoking history, exposure history, co-morbidities, signs and symptoms at admission, radiological features by lung computed tomography (CT) scan and COVID-19 severity were displayed in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinical co-variates.Total *N* = 1859Non-cancer *N* = 1794 (97)Cancer *N* = 65 (3)*P*-valueCo-variatesAge, median (IQR), years59 (45, 68)59 (45, 68)63 (54, 70)0.054Age0.194  \<65 years1199 (65)1162 (65)37  ≥65 years660 (36)632 (35)28Male934 (50)903 (50)310.706Smoking history111 (6)105 (6)60.019  Former smoker66 (4)60 (3)6  Current smoker45 (2)45 (3)0Exposure history0.036  Huanan Seafood Market4 (0.2)3 (0.2)1  Close contact with infected persons78 (4)77 (4)1Co-morbidity  ASCVD268 (14)259 (14)9\>0.999  Arterial hypertension579 (31)559 (31)20\>0.999  Diabetes mellitus262 (14)250 (14)120.303  COPD61 (3)60 (3)10.722  Chronic kidney disease45 (2)44 (3)1\>0.999  Gastro-intestinal disease98 (5)93 (5)50.388Signs and symptoms  Fever^a^1448 (78)1399 (78)490.608  Temperature (°C)^b^36.6 (36.4, 37.0)36.6 (36.4, 37.1)36.6 (36.5, 36.9)0.464  Shortness of breath716 (39)685 (38)310.123  Dry cough619 (43)597 (43)220.294  Wet cough715 (39)684 (38)310.12  Fatigue695 (37)670 (37)250.858  Nausea and/or vomiting124 (9)116 (8)80.21  Diarrhea243 (13)234 (13)90.852  Chills281 (19)274 (20)70.137  Rhinorrhea33 (2)32 (2)1\>0.999  Myalgia315 (17)305 (17)100.867  Headache107 (6)105 (6)20.583Radiological co-variates  Bilateral pneumonia1570 (88)1515 (88)550.693  Consolidation326 (19)314 (18)120.754  Ground-glass opacity1331 (75)1287 (75)440.6  Patchy shadows736 (42)700 (41)360.005COVID-19 severity0.003  Mild34 (2)33 (2)1  Moderate1170 (63)1141 (64)29  Severe453 (24)433 (24)20  Critical202 (11)187 (10)15Data are median (IQR) or *n* (%).*ASCVD* cardio- and cerebro-vascular disease, *COPD* chronic obstructive pulmonary disease^a^≥1 temperature ≥ 37.3 °C from onset of symptoms to admission.^b^Admission temperature.

Of the 1859 subjects, 65 (3%) had cancer 47 survived; 18 died. None of the 18 subjects died from cancer. Detailed data were available in 59 subjects (Supplement Table [1)](#MOESM1){ref-type="media"}. Most had solid cancers including breast (*N* = 8), thyroid (*N* = 7) and gastric cancers (*N* = 6). 9 subjects had hematological cancers including lymphoma (*N* = 4), leukemia (*N* = 3), myelodysplastic syndrome (*N* = 1) and plasma cell myeloma (*N* = 1). Twenty-one subjects were diagnosed \>5 years, 25, 1--5 years ago and 13, ≤1 year before their COVID-19 admission. In 41 subjects the cancer was in complete remission and in 18 in less than complete remission. No subjects were receiving anti-cancer therapy on admission for COVID-19. Sixteen of them received anti-cancer therapy \<1 month before admission. Therapies included surgery (*N* = 1), chemotherapy (*N* = 12), targeted therapy (*N* = 6) and radiation therapy (*N* = 1). Demographic and clinical characteristics of COVID-19 subjects with cancers were shown in Supplement Table [2](#MOESM1){ref-type="media"}.

Comparison of cancer and non-cancer subjects with COVID-19 by admission clinical co-variates {#Sec9}
--------------------------------------------------------------------------------------------

Subjects with cancer were more likely to be old (median 63 years, interquartile range \[IQR\] 54--70 years versus 59 years, \[IQR\] 46--68 years; *P* = 0.054; Table [1](#Tab1){ref-type="table"}), to be smokers (9% versus 6%, *P* = 0.019) and to have visited the Huanan Seafood Whole Sale Market (1 versus 3; *P* = 0.036). There were no significant differences in age distribution (57% versus 65%, \<65 years; *P* = 0.194) or ≥1 prior co-morbidity (46% versus 47%; *P* \> 0.999). Prior co-morbidities included ASCVD (*N* = 9), arterial hypertension (*N* = 20), diabetes mellitus (*N* = 12), COPD (*N* = 1), chronic kidney disease (*N* = 1) and gastro-intestinal disease (*N* = 5).

Signs and symptoms on admission including temperature, shortness of breath, dry and wet coughs, fatigue, nausea and/or vomiting, diarrhea, chills, rhinorrhea, myalgia and headache were similar between subjects with and without cancer. Subjects with cancer subjects were more likely to have patchy lung infiltrates on lung CT (60% versus 41%, *P* = 0.005) but similar frequencies of consolidation, bilateral pneumonia and ground-glass opacity. Subjects with cancer were more likely to have severe/critical COVID-19 severity on admission (54% versus 35%; *P* = 0.003).

Comparison of cancer and non-cancer subjects with COVID-19 by laboratory co-variates {#Sec10}
------------------------------------------------------------------------------------

Admission laboratory co-variates in subjects with and without cancer are displayed in Table [2](#Tab2){ref-type="table"}. Cancer subjects had significant higher median concentrations of neutrophils (5 × 10 E + 9/L \[IQR 3--7 × 10 E + 9/L\] versus 3 × 10 E + 9/L \[IQR 2--5 × 10 E + 9/L\]; *P* = 0.001), neutrophil-to-lymphocyte ratio (NLR) (4 \[IQR 3--8\] versus 3 \[IQR 2--5\];  *P *\< 0.001) and lower median concentrations of lymphocytes (0.9 × 10 E + 9/L \[IQR 0.6--1.3 × 10 E + 9/L\] versus 1.1 × 10 E + 9/L \[IQR 0.8--1.6 ×10 E + 9/L\]; *P* \< 0.001) and hemoglobin (120 × g/L \[IQR 102--132 × g/L\] versus 128 × g/L \[IQR 117--139 × g/L\]; *P* \< 0.001). There were no significant differences in platelet concentrations or percentages of lymphocyte subsets including CD3-positive cells, CD4-positive cells, CD8-positive cells, natural-killer (NK) cells or B lymphocytes or in CD4-positive/CD8-positive ratio. Median plasma concentration of tumor necrosis factor (TNF)-α was lower in subjects with cancer (2.9 pg/ml \[1.8--3.5 pg/ml\] versus 3.4 pg/ml \[2.2--5.5 pg/ml\]; *P* = 0.029). Plasma concentrations of other cytokines including interleukin (IL)-4, IL-6, IL-10, and interferon (IFN)- γ were similar.Table 2Laboratory co-variates.Co-variates (normal range)*N*TotalNon-cancerCancer*P* valueCBC Neutrophils ×10 E + 9/L (1.8--6.3)18163 (2, 5)3 (2, 5)5 (3, 7)0.001 Lymphocytes ×10 E + 9/L (1.1--3.2)18471.0 (0.8, 1.6)1.1 (0.8, 1.6)0.9 (0.6, 1.3)0.001 Monocytes ×10 E + 9/L (0.1--0.6)18050.4 (0.3, 0.5)0.4 (0.3, 0.5)0.4 (0.2, 0.7)0.32 Hemoglobin, g/L (115--150)1433128 (117, 139)128 (117, 139)120 (102, 132)\<0.001 Platelets ×10 E + 9/L (125--350)1814203 (155, 264)203 (155, 263)216 (157, 284)0.479 NLR18143 (2, 5)3 (2, 5)4 (3, 8)\<0.001Inflammation co-variates CRP, mg/L (\<8)137113 (3, 51)13 (3, 49)27 (6, 66)0.047 Procalcitonin, ng/ml (\<0.5)16430.06 (0.05, 0.1)0.05 (0.05, 0.1)0.1 (0.06, 0.2)0.001 LDH, U/L (109--245)1729212 (170, 292)211 (170, 289)252 (196, 391)\<0.001 Ferritin, ng/ml (4.6--204)308567 (246, 1218)553 (242, 1209)817 (323, 1599)0.119Coagulation co-variates aPTT, s (28--43.5)135634 (30, 38)34 (30, 38)35 (32, 40)0.009 Fibrinogen, g/L (2--4)13233.7 (2.9, 4.6)3.7 (2.9, 4.6)3.8 (3.4, 4.6)0.222 D-dimer, mg/L (\<0.5)16020.4 (0.2, 1.1)0.4 (0.2, 1.0)0.6 (0.2, 4.0)0.043Biochemistry co-variates ALT, U/L (5--35)183238 (22, 67)38 (22, 67)36 (24, 67)0.882 AST, U/L (8--40)183032 (22, 49)32 (22, 49)35 (27, 58)0.039 Total bilirubin, μmol/L (5.1--19)158614 (10, 19)14 (10, 19)15 (11, 29)0.069 Creatine kinase, U/L (26--140)149388 (54, 165)88 (54, 163)102 (52, 282)0.164 BNP, pg/ml (\<100)83861 (18, 242)60 (17, 238)85 (30, 679)0.042 Myoglobin, ng/ml (\<140)97235 (21, 73)34 (21, 71)41 (31, 303)0.004 Troponin I, ng/L (\<26.2)10834 (1, 14)4 (1, 14)8 (3, 34)0.006 BUN, mmol/L (2.9--8.2)18154.9 (3.9, 6.7)4.9 (3.9, 6.7)5.3 (3.8, 9.9)0.255 Scr, μmol/L (44--106)181371 (59, 85)71 (60, 85)65 (55, 82)0.076Lymphocyte subsets CD3+, (58--84%)75971 (62, 78)72 (62, 78)68 (58, 82)0.877 CD4+, (25--51%)75941 (32, 48)41 (33, 48)39 (29, 49)0.373 CD8+, (14--39%)75923 (17, 30)23 (17, 30)21 (17, 32)0.793 NK-cells (3--30%)56110 (6, 16)10 (6, 16)8 (5, 18)0.688 B-cells (4--18%)56112.6 (8.6, 18)12.7 (8.7, 18)12.6 (6.2, 19.3)0.828 CD4+/CD8+ ratio (0.41--2.72)7551.9 (1.4, 2.7)1.9 (1.4, 2.7)2.1 (1.4, 3.1)0.462Cytokines IL-4, pg/ml (0.1--3.2)5053 (2, 4)3 (2, 4)2 (1, 3)0.32 IL-6, pg/ml (0.1--2.9)85710 (4, 42)10 (4, 42)17 (7, 102)0.085 IL-10, pg/ml (0.1--5)5054 (3, 6)4.3 (2.9, 5.6)4.4 (2.7, 7.9)0.642 TNF-α, pg/ml (0.1--23)5053.3 (2.2, 5.4)3.4 (2.2, 5.5)2.9 (1.8, 3.5)0.029 IFN-γ, pg/ml (0.1--18)5053.1 (2.0, 4.1)3.1 (2.0, 4.1)2.7 (1.8, 4.0)0.447Data are median (IQR).*NLR* neutrophil-to-lymphocyte ratio, *CRP* c-reactive protein, *LDH* lactate dehydrogenase, *aPTT* activated partial thromboplastin time, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *BNP* B-type natriuretic peptide, *BUN* blood urea nitrogen, *Scr* serum creatinine, *IL* interleukin, *TNF* tumor necrosis factor, *IFN* interferon.

Cancer subjects had higher median serum concentrations of C-reactive protein (CRP, 27 mg/L \[IQR 6--66 mg/L\] versus 13 mg/L \[IQR 3--49 mg/L\]; *P* = 0.047), procalcitonin (0.1 ng/ml \[IQR 0.06--0.2 ng/ml\] versus 0.05 ng/ml \[IQR 0.05--0.1 ng/ml\]; *P* = 0.001), and D-dimer (0.6 mg/L \[IQR 0.2--4.0 mg/L\] versus 0.4 mg/L \[IQR 0.2--1.0 mg/L\]; *P* = 0.043) and longer activated partial thromboplastin time (aPTT, median 35 s \[IQR 32--40 s\] versus 34 s \[IQR 30--38 s\]; *P* = 0.009). No significant difference was found in serum concentrations of ferritin or fibrinogen.

Cancer subjects had higher median activities of lactate dehydrogenase (LDH) (252 U/L \[IQR 196--391 U/L\] versus 211 U/L \[IQR 170--289 U/L\]; *P* \< 0.001), aspartate aminotransferase (AST, 35 U/L \[27--58 U/L\] versus 32 U/L \[22--49 U/L\]; *P* = 0.039), concentrations of B-type natriuretic peptide (BNP, 85 pg/ml \[30--679 pg/ml\] versus 60 pg/ml \[17--238 pg/ml\]; *P* = 0.042), myoglobin (41 ng/ml \[31--303 ng/ml\] versus 34 ng/ml \[21--71 ng/ml\]; *P* = 0.004) and troponin I (8 ng/L \[3--34 ng/L\] versus 4 ng/L \[1--14 ng/L\]; *P* = 0.006). There were no significant differences in activities of alanine aminotransferase (ALT) or creatine kinase or concentrations of total bilirubin, blood urea nitrogen (BUN) or serum creatinine (Scr).

Complications and outcomes of subjects with cancer and without cancer {#Sec11}
---------------------------------------------------------------------

As shown in Table [3](#Tab3){ref-type="table"}, subjects with cancer had higher incidence of ARDS (19 \[29%\] versus 208 \[12%\]; *P* \< 0.001), bacterial infection (30 \[46%\] versus 533 \[30%\]; *P* = 0.005), septic shock (7 \[11%\] versus 57 \[4%\], *P* = 0.007), acute kidney injury (9 \[14%\] versus 90 \[5%\]; *P* = 0.002), cardiac injury (14 \[22%\] versus 215 \[12%\]; *P* = 0.021), gastrointestinal bleeding (5 \[8%\] versus 29 \[2%\]; *P* \< 0.001) and multiple organ failure (12 \[19%\] versus 117 \[7%\]; *P* \< 0.001).Table 3Complications and therapy.Total *N* = 1859Non-cancer *N* = 1794Cancer *N* = 65*P-*valueComplications ARDS227 (12)208 (12)19\<0.001 Bacterial infections563 (30)533 (30)300.005 Septic shock64 (4)57 (4)70.007 Acute kidney injury99 (5)90 (5)90.002 Heart injury229 (12)215 (12)140.021 Abnormal LFT456 (25)440 (25)160.984 Gastro-intestinal bleeding34 (2)29 (2)5\<0.001 Coagulopathy49 (3)47 (3)20.821 Multiple organ failure129 (7)117 (7)12\<0.001Therapy Antibiotics1559 (85)1497 (85)620.019 Anti-fungal drugs71 (4)64 (4)70.005 Oseltamivir757 (41)729 (41)280.697 Umifenovir1386 (75)1343 (75)430.110 Lopinavir/ritonavir339 (23)328 (24)110.357 Interferon alpha387 (21)363 (20)240.001 Corticosteroids753 (41)725 (40)280.670 IVIG506 (29)478 (29)280.009 High-flow nasal cannula oxygen therapy233 (16)214 (15)190.001 Non-invasive mechanical ventilation145 (8)130 (7)15\<0.001 Invasive mechanical ventilation85 (5)78 (4)70.015 ECMO4 (0.2)4 (0.2)0\>0.999 CRRT23 (1)22 (1)10.561Outcomes Death209 (11)191 (11)18\<0.001 Time from illness onset to ICU admission, median (IQR), days14 (10, 20)14 (10, 20)14 (7, 21)0.790 Time from illness onset to repeated negative SARS-CoV-2 tests, median (IQR), days22 (17, 28)22 (17, 28)20 (16, 28)0.379 Time from illness onset to admission, median (IQR), days10 (7, 15)10 (7, 15)10 (7, 13)0.104 Time from illness onset to progression, median (IQR), days10 (7, 15)10 (5, 14)11 (6, 18)0.284 Time from illness onset to outcome^a^, median (IQR), days30 (23, 37)30 (23, 37)28 (21, 35)0.209 Time from diagnosis to outcome^a^, median (IQR), days19 (13, 27)19 (13, 27)21 (14, 27)0.503 Time from admission to outcome^a^, median (IQR), days18 (12, 23)18 (12, 23)18 (13, 26)0.353*LFT* liver function test, *ARDS* acute respiratory distress syndrome, *IVIG* intravenous immunoglobin, *ECMO* extra-corporeal membrane oxygenation, *CRRT* continuous renal replacement therapy, *ICU* intensive care unit.^a^Outcome refers to discharged alive or died.

Subjects with cancer were also more likely to receive antibiotics (62 \[95%\] versus 1497 \[85%\]; *P* = 0 .019), anti-fungal drugs (7 \[11%\] versus 64 \[4%\]; *P* = 0 .005), intra-tracheal α-interferon (24 \[37%\] versus 363 \[20%\]; *P* = 0.001), immunoglobin intravenous (IVIG, 28 \[44%\] versu*s* 478 \[29%\]; *P* = 0 .009), high-flow nasal cannula oxygen (19 \[31%\] versus 214 \[15%\]; *P* = 0 .001), invasive (7 \[11%\] versus 78 \[4%\]; *P* = 0 .015) and non-invasive (15 \[23%\] versus 130 \[7%\]; *P* \< 0.001) mechanical ventilation. There was no significant difference in use of extra-corporeal membrane oxygenation (ECMO) or continuous renal replacement therapy (CRRT).

Subjects with cancer were more likely to die from COVID-19 (18 \[28%\] versus 191 \[11%\]; *P* \< 0.001). There were no significant differences in interval from hospital admission to ICU admission, repeatedly negative SARS-CoV-2 tests, interval from admission to recovery, COVID-19 progression or death.

Multi-variable analyses {#Sec12}
-----------------------

We analyzed co-variates associated with risk of in-hospital death from COVID-19 in a Cox regression model including co-variates with *P* \< 0.05 in uni-variable analyses excluding those with co-linearity (Supplement Table [2](#MOESM1){ref-type="media"}). Age *per* year increase (HR = 1.05 \[1.04, 1.07\]; *P* \< 0.001), male (HR = 1.53 \[1.09, 2.14\]; *P* = 0.013), admission COVID-19 severity severe/critical (HR = 28.2 \[13.8, 57.6\]; *P* \< 0.001), current smoking (HR 2.00 \[1.10, 3.66\]; *P* = 0.024), admission temperature *per* °C (HR = 1.24 \[1.03, 1.50\]; *P* = 0.026), platelet concentration *per* 10 E + 9/L increase (HR = 0.996 \[0.994, 0.998\]; *P* = 0.001) and plasma D-dimer concentration *per* mg/L increase (HR = 1.04 \[1.02, 1.05\]; *P* \< 0.001) but not having cancer (HR = 1.59 \[0.95, 2.69\]; *P* = 0.081; Table [4](#Tab4){ref-type="table"}) were significantly associated with risk of in-hospital death from COVID-19.Table 4Multi-variable analyses of co-variates associated with in-hospital death of persons with cancer.All\<65 years≥65 yearsHR (95% CI)*P* valueHR (95% CI)*P* valueHR (95% CI)*P* valueAge, years1.05 (1.04, 1.07)\<0.0011.05 (1.02, 1.09)0.0011.05 (1.02, 1.07)\<0.001Male1.53 (1.09, 2.14)0.0131.82 (0.999, 3.30)0.0501.50 (0.998, 2.27)0.051Severity (severe/critical)28.17 (13.78, 57.62)\<0.00116.06 (6.32, 40.80)\<0.00146.10 (14.56, 145.91)\<0.001Cancer1.59 (0.95, 2.69)0.0812.45 (1.04, 5.76)0.0411.12 (0.56, 2.24)0.740Current smoking2.00 (1.10, 3.66)0.0241.22 (0.37, 4.02)0.7412.43 (1.20, 4.91)0.014Temperature at admission (°C)1.24 (1.03, 1.50)0.0261.09 (0.79, 1.50)0.6091.35 (1.05, 1.73)0.021Platelets x10E + 9/L0.996 (0.994, 0.998)0.0010.997 (0.994, 1.001)0.0990.996 (0.993, 0.998)0.002D-dimer, mg/L1.04 (1.02, 1.05)\<0.0011.21 (1.08, 1.17)\<0.0011.03 (1.01, 1.04)\<0.001

Next, we performed separate multi-variable regression analyses in subjects \< and ≥65 years after adjusting age and sex. We found having cancer was significantly associated with risk of in-hospital death from COVID-19 in subjects \<65 years (HR = 2.45 \[1.04, 5.76\]; *P* = 0.041) but not in subjects ≥65 years (HR = 1.12 \[0.56, 2.24\]; *P* = 0.740). Other risk factors in subjects \<65 years included age per year increase (HR = 1.05 \[1.02, 1.09\]; *P* = 0.001, COVID-19 severity severe/critical at admission (HR = 16.1 \[6.3, 40.8\]; *P* \< 0.001) and plasma D-dimer concentration per mg/L increase (HR = 1.21 \[1.08, 1.17\]; *P* \< 0.001). In subjects ≥65 years age per year increase (HR 1.05 \[1.02, 1.07\]; *P* \< 0.001), admission COVID-19 severity severe/critical (HR = 46.1 \[14.6, 145.9\]; *P* \< 0.001), platelet concentration *per* 10 E + 9/L increase (HR = 0.996 \[0.993-0.998\]; *P* = 0.002) and plasma D-dimer concentration *per* mg/L increase (HR 1.03 \[1.01, 1.04\]; *P* \< 0.001) were correlated with risk of in-hospital death from COVID-19.

Comparison of co-variates in subjects with cancer living or dying from COVID-19 {#Sec13}
-------------------------------------------------------------------------------

18 subjects with cancer died. There was no difference in median age (68 years, IQR 56--78 years versus 62 years, IQR 51--67 years; *P* = 0.146, Supplement Table [3](#MOESM1){ref-type="media"}), sex (*P* = 0.58) or frequencies of prior co-morbidities between non-survivors and survivors. Non-survivors were more likely to have had shortness of breath on admission (78% versus 36%; *P* = 0.005) but there were no significant differences in other signs or symptoms on admission or in findings on lung CT scan. Non-survivors were more likely to have had severe/ critical COVID-19 on admission than survivors (94% versus 38%, *P* \< 0.001). Non-survivors had significantly higher median concentrations/activities of neutrophils, CRP, procalcitonin, LDH, ferritin, D-dimer, ALT, AST, total bilirubin, creatine kinase, BNP, myoglobin, troponin I, BUN, Scr, and NLR, and lower concentrations of lymphocytes (Supplement Table [4](#MOESM1){ref-type="media"}). Percentages of CD3-, CD4- and CD8-positive T-cells, CD4/CD8 ratio and B-cells were similar between survivors and non-survivors. In contrast, percentage of natural killer (NK)-cells was significantly lower in non-survivors (4% \[IQR 2--6%\] versus 14% \[IQR 7-18%\]; *P* = 0.008). Non-survivors had higher concentrations of IL-6 (287 pg/ml \[IQR 22--686 pg/ml\] versus 12 pg/ml \[IQR 5--27 pg/ml\]; *P* = 0.001) and IL-10 (10 pg/ml \[IQR 4--18 pg/ml\] versus 4 pg/ml \[IQR 3--5 pg/ml\]; *P* = 0.012). There was no significant difference in serum concentrations of IL-4, TNF-α or IFN-γ. Time from admission to recovery, discharge or death was significantly shorter in non-survivors (21 days \[IQR 15--30 days\] versus 31 days \[IQR 24--37 days\]; *P* = 0.002; Supplement Table [5](#MOESM1){ref-type="media"}).

We further compared co-variates between subjects with solid and hematological cancers (Supplement Table [6](#MOESM1){ref-type="media"}). Subjects with hematological cancer were more likely to be young (39 years \[IQR 23--66 years\] versus 63 years \[IQR 57--69 years\]; *P* = 0.019), to have lower hemoglobin concentration (92 g/L \[IQR 86--116 g/L\] versus 121 g/L \[IQR 106--133 g/L\]; *P* = 0.011) and longer aPTT (42 s \[IQR 38--48 s\] versus 35 s \[IQR 32--38 s\]; *P* = 0.001). There was no difference in other co-variates including signs and symptoms, laboratory co-variates or co-morbidities on admission. Rates of ICU admission bacterial co-infections, of ARDS and of in-hospital death from COVID-19 (2/9 versus 14/50; *P* \> 0.999) were similar. We also compared co-variates in subjects in complete remission or not. (Supplement Table [7](#MOESM1){ref-type="media"}) Subjects not in complete remission were more likely to be young (54 years \[IQR 27-66 years\] versus 63 years \[IQR 58--71 years\]; *P* = 0.034), to have a lower incidence of diabetes and lower median concentrations of hemoglobin (100 g/L \[IQR 89--107 g/L\] versus 129 g/L \[IQR 118--137 g/L\]; *P* \< 0.001) and plasma IL-6 (43 pg/ml \[13--593 pg/ml\] versus 11 pg/ml \[3--37 pg/ml\]; *P* = 0.022) and a higher risk of death (9/18 versus 7/41; *P* = 0.013).

Discussion {#Sec14}
==========

There is controversy whether having cancer is associated with an increased risk of death from COVID-19. Some studies report an association \[[@CR1]--[@CR3], [@CR5]--[@CR9], [@CR13]--[@CR18]\], others not \[[@CR19]--[@CR26]\]. These differences could be related to cancer patients' age or other factors. We studied 1859 consecutive subjects with COVID-19, 65 of whom also had cancer. Detailed data were available in 59. The strongest risk factor for in-hospital death from COVID-19 in all subjects and in subjects with cancer was COVID-19 severity on admission. However, we also found having cancer increased risk of in-hospital death from COVID-19 in subjects \<65 years but not in those ≥65 years. We also found risk of death in persons with cancer only operated in those \<65 years and in those not in complete remission. Type of cancer (solid or hematological) was not significantly correlated with risk of in-hospital death from COVID-19.

There are limitations to our study. It was retrospective, has relatively few subjects with cancer but \>1800 controls and lacks a validation cohort. Nevertheless, we think our data may be informative in treating persons with cancer and COVID-19.
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